Merit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for the quarter ended June 30, 2026, after the stock market closes on Thursday, July 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time. Interested parties can pre-register for the call or access a live webcast and slide deck via Merit's website.
Merit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026
Merit Medical Systems, Inc. (NASDAQ: MMSI) has announced it will release its financial results for the quarter ended June 30, 2026, after the stock market closes on Thursday, July 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time to discuss the results. Merit Medical develops, manufactures, and distributes proprietary medical devices for a variety of interventional, diagnostic, and therapeutic procedures globally.
Merit Medical schedules July 30 results and investor call
Merit Medical Systems (NASDAQ: MMSI) has announced it will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. The company will host an investor conference call on the same day at 4:30 p.m. Eastern. Investors can register for the call and access a live webcast and slide deck via Merit Medical's website.
Merit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its second-quarter 2026 financial results after the stock market closes on Thursday, July 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time. Interested parties can pre-register for the call or access a live webcast and slide deck via links provided by the company.
MMSI - Merit Medical Systems Inc Latest SEC Filings
This article provides the latest SEC filings for Merit Medical Systems Inc. (MMSI), along with comprehensive financial data, performance metrics, and key statistics. It includes information on the company's valuation, profitability, growth rates, and institutional ownership, offering a snapshot of its financial health and market position.
Enterprise value to EBITDA forward of Merit Medical Systems, Inc. – NASDAQ:MMSI
The article provides financial information for Merit Medical Systems, Inc. (NASDAQ: MMSI), focusing on its enterprise value to EBITDA forward. It presents this data within the context of TradingView's platform, indicating various analytical tools and market data services used.
Price to book forward of Merit Medical Systems, Inc. – NASDAQ:MMSI
This article presents information on the "Price to book forward" metric for Merit Medical Systems, Inc. (NASDAQ: MMSI). It indicates that the data is provided by ICE Data Services and FactSet, with SEC filings by Quartr. The core content is about financial metrics for the specified company.
(MMSI) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Merit Medical Systems Inc. (NASDAQ: MMSI), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies (Long, Breakout, Short) with entry, target, and stop-loss zones, along with multi-timeframe signal analysis for support and resistance levels.
Price to sales forward of Merit Medical Systems, Inc. – NASDAQ:MMSI
This article provides the "Price to sales forward" metric for Merit Medical Systems, Inc. (NASDAQ: MMSI). It appears to be a financial data snippet from TradingView, focusing on the company's valuation.
Price to earnings forward of Merit Medical Systems, Inc. – DUS:MM3
This article displays the "Price to earnings forward" value for Merit Medical Systems, Inc. (DUS:MM3) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content primarily comes from TradingView, with data provided by ICE Data Services, FactSet, and Quartr.
Merit Medical Systems, Inc. Actuals & Estimates (NASDAQ:MMSI)
This article provides an overview of Merit Medical Systems, Inc. (NASDAQ: MMSI), including its current stock price, market capitalization, and historical performance. It also details financial estimates, analyst forecasts for future price targets, and key financial metrics like earnings, revenue, and EBITDA. Additionally, the piece addresses frequently asked questions regarding the company's financials and stock trading.
MMSI Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Merit Medical Systems, Inc. (MMSI) stock for 2027, based on analyst ratings and current financial data. It includes details on the stock's current price, historical performance, earnings reports, revenue, market capitalization, and volatility, offering insights for potential investors.
Merit Medical Systems Inc (MMSI) Valuation: PE, PB & Fair Value Analysis
Merit Medical Systems Inc (MMSI) has a current valuation score of 6.38, placing it 185th out of 204 companies in the Healthcare Equipment & Supplies industry. Its P/E ratio is 27.77, which is significantly below its recent high and slightly above its recent low. The article notes that relevant data for P/B, P/S, and P/CF ratios has not yet been disclosed by the company.
Merit Medical Systems Inc (MMSI) Institutional Confidence
Merit Medical Systems Inc (MMSI) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion has increased by 10.26% quarter-over-quarter, with Steven Cohen being the largest institutional shareholder. The article also lists major institutional shareholders and their recent activity.
Merit Medical Systems Inc (MMSI) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Merit Medical Systems Inc (MMSI) stock performance, focusing on its dividend and stock split history. It notes that MMSI has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock prices, market capitalization, and P/E ratio for MMSI.
Merit Medical (MMSI) CHRO makes 65-share charitable gift
Merit Medical Systems' CHRO, Michel J. Voigt, made a charitable gift of 65 common shares on June 15, 2026, receiving no consideration. Following this transaction, Voigt holds 46,062 direct common shares and 2,265 shares in a 401(k) plan, along with non-qualified stock options for over 17,000 shares. This was a charitable disposition, not a market sale, and does not represent selling pressure on the company's stock.
Is the Options Market Predicting a Spike in Merit Medical Systems Stock?
The options market indicates that investors are predicting a significant move for Merit Medical Systems (MMSI) stock, as evidenced by the high implied volatility of its July 17, 2026 $90 Call option. Despite this, analysts currently rate MMSI as a Zacks Rank #3 (Hold), with recent earnings estimate revisions trending slightly downwards. This situation suggests a potential trading opportunity for options traders who might look to sell premium.
MedtechVISION 2026 to focus on medtech disruption
MedtechWOMEN announced the theme for its MedtechVISION 2026 Annual Conference, "The Breakthrough Imperative: Winning in an Ever-Changing Landscape," which will address medtech disruption caused by capital, AI, and geopolitics. The event, limited to 280 attendees, will feature Dr. Bayo Curry-Winchell as an inspirational patient keynote and Martha Aronson, CEO of Merit Medical Systems, discussing leadership in global healthcare. MedtechWOMEN is also accepting nominations for the Ferolyn Powell Leadership Award, recognizing those who advance medtech leadership and patient-centered innovation.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical Systems, Inc. (MMSI) is positioned for growth due to its strong product portfolio and continued investment in research and development, despite challenges from tariffs and China's macro pressures. The company's therapeutic products are a key growth engine, boosted by acquisitions like View Point Medical which expanded its oncology platform. While facing tariff-related cost pressures and OEM segment weakness, its estimate revision trend for 2026 is positive.
Merit Medical Systems (MMSI) CLO reports charitable gift of 2,000 shares
Merit Medical Systems' Chief Legal Officer, Brian G. Lloyd, reported a charitable gift of 2,000 common shares. No consideration was received for this transaction, which reduced his direct holdings. After the gift, Lloyd directly owns 60,132 common shares and indirectly holds 2,000 shares through a 401(k) plan, in addition to various non-qualified stock options.
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
Merit Medical Systems, Inc. (MMSI) is positioned for growth due to its strong product portfolio, including therapeutic products and the acquisition of View Point Medical, which expands its oncology platform. The company's focus on product innovation, like the Resilience Through-the-Scope Esophageal Stent, also supports future growth. However, challenges such as tariffs, weakness in the OEM segment, China macro pressure, and competitive markets pose headwinds for MMSI.
Merit Medical Systems (MMSI) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
This article summarizes Merit Medical Systems' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. Key points include recent strategic and operational changes like re-segmentation and CEO transition, growth driven by volume and acquisitions in foundational and therapeutic segments, and a focus on disciplined M&A. The company reported strong Q1 organic growth, rebounding OEM business, and a commitment to realistic financial guidance and operating margin expansion.
A Look At Merit Medical Systems (MMSI) Valuation As Insider Buying Follows Undervaluation Claims
Merit Medical Systems (MMSI) is currently trading at an estimated 34.1% discount to its intrinsic value and 38.9% below analyst targets, suggesting a potential undervaluation despite a challenging year for its stock. The company's strong growth in cardiovascular and endoscopy, new product development, and recent acquisitions position it well for long-term revenue growth driven by increasing demand for medical procedures. However, its P/E ratio of 27.6x is higher than the industry average, raising questions about whether the market is being overly cautious or realistic about its future growth prospects.
(MMSI) Risk Channels and Responsive Allocation
Merit Medical Systems Inc. (NASDAQ: MMSI) is showing a near-term weak sentiment that may lead to a resumption of long-term weakness after a neutral shift. An exceptional 35.0:1 risk-reward short setup is identified, targeting a 10.3% downside against a 0.3% risk. AI models have generated three distinct trading strategies for MMSI: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each tailored to different risk profiles.
MMSI Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Merit Medical Systems Inc (MMSI) financials, detailing its revenue breakdown, profitability margins, and competitor comparison. The company generates significant revenue from Peripheral Intervention, and exhibits a gross margin of 48.39%, an operating margin of 11.56%, and a net margin of 10.74%. MMSI's financial performance is benchmarked against industry leaders like IRTC and VCYT, highlighting its competitive standing.
Assessing Merit Medical Systems (MMSI) After Share Price Slide And Conflicting Valuation Signals
Merit Medical Systems (MMSI) has seen its share price decline significantly over the past year, prompting an evaluation of its current valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 33.8%, its P/E ratio of 27.0x is above Simply Wall St's "Fair Ratio" of 21.8x, indicating it might be overvalued by this metric. The article highlights these conflicting signals and introduces the concept of "Narratives" for investors to develop their own detailed valuation based on varying assumptions regarding company growth and market conditions.
Why Merit Medical (MMSI) is a top growth stock for the long term
This article identifies Merit Medical (MMSI) as a top growth stock for long-term investment. The company's strong fundamentals and potential for sustained growth are highlighted as key reasons for its attractiveness to investors. Further details would likely delve into specific financial metrics, market position, and future outlook.
Merit Medical Systems (NasdaqGS:MMSI) Stock Forecast & Analyst Predictions
Merit Medical Systems (MMSI) is expected to grow earnings by 12.5% and revenue by 5.7% annually, with analysts forecasting a 11.5% EPS growth. Recent updates include increased EPS estimates for 2026, a lowered consensus price target of $90.64, and the acquisition of Viewpoint Medical for $140 million, expanding its oncology portfolio. The company reported strong Q1 2026 results, surpassing estimates and raising full-year revenue guidance, while insider transactions show more selling than buying over the past year.
The Bull Case For Merit Medical Systems (MMSI) Could Change Following Governance Bylaw Overhaul And New Director Appointment
Merit Medical Systems (MMSI) recently updated its corporate bylaws and appointed Scott R. Ward, a veteran medical device executive, to its Board of Directors. These changes are expected to improve governance and oversight, aligning the company's corporate machinery with its growth plans and acquisition strategies. While these are positive developments, the company still faces near-term challenges related to WRAPSODY reimbursement delays, tariffs, and APAC market pressures.
The Bull Case For Merit Medical Systems (MMSI) Could Change Following Governance Bylaw Overhaul And New Director Appointment
Merit Medical Systems recently adopted new bylaws and appointed Scott R. Ward to its Board, changes that could support governance and oversight. While these updates are seen as incrementally positive for the company's investment narrative, the article emphasizes that near-term challenges like WRAPSODY reimbursement delays and tariff pressures remain key drivers of risk and catalysts. The company forecasts revenue of $1.8 billion and earnings of $197.1 million by 2029, suggesting a 53% upside based on fair value estimates.
(MMSI) Movement as an Input in Quant Signal Sets
This article analyzes Merit Medical Systems Inc. (NASDAQ: MMSI) stock movement using quantitative signals. It highlights a positive near-term sentiment that may shift, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting an 11.5% gain. The piece outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, along with multi-timeframe signal analysis.
Merit Medical (NASDAQ: MMSI) director exercises 21,250 stock options in cash
Merit Medical (NASDAQ: MMSI) director Thomas J. Gunderson exercised stock options to acquire 21,250 shares of common stock on May 20, 2026. He paid cash for the exercise price of $52.17 per share, and no shares were sold in connection with these transactions. Following these exercises, Gunderson directly owns 60,741 shares of common stock, and the exercised option grants now have zero remaining shares.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs, total holdings 8,040 shares
Merit Medical Systems Inc. (NASDAQ: MMSI) director Silvia M. Perez was granted 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan. These RSUs will vest on May 3, 2027, subject to her continued service, increasing her direct holdings to 8,040 shares. This transaction was reported via a Form 4 filing and represents an equity grant rather than an open-market purchase.
RSU grant to Merit Medical (MMSI) director adds 3,457 share units
Merit Medical Systems director Scott R. Ward received a routine grant of 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan. These RSUs, granted at no purchase price, will vest on May 3, 2027, provided Ward continues his service with the company. This compensation-related award is viewed as a neutral event for the broader investment case, aligning director interests with shareholders.
Director at Merit Medical (MMSI) receives 3,457 RSUs equity grant
Merit Medical Systems director Stephen C. Evans was granted 3,457 Restricted Stock Units (RSUs) as part of the company's 2026 Equity Incentive Plan. This equity award, which has no cash cost to the director, increases his directly held common shares to 10,266. The RSUs are set to vest on May 3, 2027, provided he continues his service with the company until that date.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs under 2026 equity plan
Merit Medical Systems (NASDAQ: MMSI) director Laura S. Kaiser was granted 3,457 Restricted Stock Units (RSUs) under the company's 2026 Equity Incentive Plan. This grant, valued at $0.00 per share, is a form of compensation and not an open-market transaction. The RSUs will vest on May 3, 2027, provided she continues her service to the company, bringing her total direct holdings to 13,352 shares.
Merit Medical (NASDAQ: MMSI) director granted 3,457 RSUs and holds options
Merit Medical Systems Inc. director Thomas J. Gunderson was granted 3,457 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan, which will vest on May 3, 2027, contingent on his continued service. Following this award, Gunderson holds 39,491 shares of Common Stock and stock options for an additional 21,250 shares at an exercise price of $52.17. The filing is categorized as neutral in terms of impact and sentiment.
Director receives 3,457 RSUs at Merit Medical (NASDAQ: MMSI)
Merit Medical Systems Inc. director F. Ann Millner was granted 3,457 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs are scheduled to vest on May 3, 2027, provided her continuous service to the company. Following this compensation-related grant, her direct holdings in the company's common stock amount to 38,000 shares.
Merit Medical Updates Governance and Elects New Director
Merit Medical Systems shareholders approved new equity and stock purchase plans, updated bylaws to enhance governance, and re-elected directors. The company also announced the election of Scott R. Ward to its board, reinforcing its leadership and strategic direction. An analyst has a Buy rating on MMSI with a $96.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to strong financial performance offset by weak technical conditions and a demanding valuation.
Merit Medical (NASDAQ: MMSI) holders okay 2026 equity and ESPP plans
Merit Medical Systems, Inc. shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at their annual meeting. The plans allow for stock-based awards and enable eligible employees to purchase common stock at a discount, respectively. Shareholders also re-elected directors, endorsed executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm for 2026.
Merit Medical (MMSI) director Scott R. Ward files initial Form 3 ownership
Merit Medical Systems Inc. director Scott R. Ward has filed an initial Form 3, which is a statement of beneficial ownership. This filing establishes his baseline disclosure as a reporting person for the company, indicating no reported transactions or derivative positions. The document itself shows his beneficial ownership to be zero, acting as an initial inventory sheet for his holdings.
Scott R. Ward, ex-Medtronic leader, joins Merit Medical board
Merit Medical Systems (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at their annual meeting on May 19, 2026. Ward, an executive with over 40 years of experience in the healthcare and medical device industry, including senior roles at Medtronic and as CEO of Cardiovascular Systems, will serve on the Board’s Governance and Sustainability and Finance and Operating Committees. This appointment is expected to provide valuable strategic insight and support the company's long-term growth and innovation goals.
Merit Medical Systems Elects Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. has elected Scott R. Ward to its Board of Directors for a three-year term, effective May 19, 2026. Ward brings over 40 years of experience in the medical device industry, including leadership roles at Medtronic and as CEO of Cardiovascular Systems, Inc. He will serve on the Governance and Sustainability and Finance and Operating Committees, contributing his strategic insights to the company's innovation and growth initiatives.
Press Release: Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
Merit Medical Systems, Inc. announced that its shareholders elected Scott R. Ward to the company's Board of Directors during its 2024 annual meeting. The appointment of Mr. Ward, who brings extensive experience from his leadership roles at Boston Scientific Corporation, expands the Board to twelve members. His expertise is expected to contribute to Merit Medical's ongoing growth and strategic objectives.
Merit Medical Systems Director Lynne N. Ward Sells 5,000 Shares in Open-Market Transaction
Merit Medical Systems Director Lynne N. Ward sold 5,000 shares of the company's stock in an open-market transaction, according to an SEC filing. The sale generated approximately $313,000 at a weighted average price of $62.61 per share, reducing Ward's direct ownership stake by 39% from 12,809 to 7,809 shares. This is her only open-market transaction in the past year, reflecting a trend of reducing her position, though she still holds shares worth about $489,000.
Merit Medical Systems (MMSI) Valuation Check After New US$270.135 Million Shelf Registration And Guidance Update
Merit Medical Systems (MMSI) recently filed a US$270.135 million shelf registration for common shares and raised its 2026 revenue guidance, yet its stock price has declined significantly. The company is considered undervalued at a 36% discount to its intrinsic value and 48% below analyst targets, primarily due to operational efficiency, product expansion, and regulatory support. However, delays in WRAPSODY CIE reimbursement and rising operating costs pose potential risks to the margin story, while its P/E ratio is still above the industry average.
Thrivent Financial for Lutherans Sells 17,162 Shares of Merit Medical Systems, Inc. $MMSI
Thrivent Financial for Lutherans reduced its stake in Merit Medical Systems by 2.3% in the fourth quarter, selling 17,162 shares to hold 732,904 shares valued at $64.6 million. Despite a recent dip in stock price, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a $92.80 price target. Merit Medical recently surpassed quarterly EPS and revenue expectations and has set a positive FY2026 EPS guidance.
Bessemer Group Inc. Buys 110,392 Shares of Merit Medical Systems, Inc. $MMSI
Bessemer Group Inc. significantly increased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 54.2% in the fourth quarter, acquiring an additional 110,392 shares to bring its total holding to 313,981 shares valued at approximately $27.7 million. Merit Medical Systems also reported better-than-expected quarterly earnings, with EPS of $0.94 and revenue of $381.9 million, surpassing analyst estimates. Despite some recent price target adjustments by analysts, the stock maintains a "Moderate Buy" consensus rating with a target price of $92.80.
How Investors May Respond To Merit Medical Systems (MMSI) Q1 Beat, Higher 2026 Revenue Outlook, Mixed Insider Moves
Merit Medical Systems (MMSI) reported a strong Q1 2026 with sales of US$381.88 million and net income of US$41.00 million, leading to an upgraded full-year 2026 revenue guidance of US$1.61 billion–US$1.63 billion. This positive financial performance is accompanied by mixed insider activity, with a director selling shares while senior executives purchased through 401(k) plans. The article explores how this improved outlook affects the company's investment narrative, considering both opportunities and risks like product recalls and tariff pressures.
Merit Medical CCO Smith acquires $99,186 in company stock
Christian Adam Smith, Chief Commercial Officer at Merit Medical Systems Inc. (NASDAQ:MMSI), acquired 1,626 shares of company stock worth $99,186 on May 11, 2026, through a 401(k) Plan. This purchase occurred as the stock traded near its 52-week low. The company recently reported strong Q1 2026 financial results, exceeding analyst expectations, and has received various analyst ratings and price targets.
